- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
CureVac NV (5CV)"CureVac NV stock price live, this page displays NASDAQ CVAC stock exchange data. View the CVAC premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the CureVac NV real time stock price chart below.
What Is the CureVac NV Stock Price Today?
The CureVac NV stock price today is 2.76.
What Is the Stock Symbol for CureVac NV?
The stock symbol for CureVac NV is ""CVAC.""
What Stock Exchange Does CureVac NV Trade On?
CureVac NV is listed and trades on the NASDAQ stock exchange.
Is CureVac NV a Good Stock to Buy?
Determining whether CureVac NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CVAC quote. (ISIN: NL0015436031)"
What Is the CureVac NV Stock Price Today?
The CureVac NV stock price today is 2.76.
What Is the Stock Symbol for CureVac NV?
The stock symbol for CureVac NV is ""CVAC.""
What Stock Exchange Does CureVac NV Trade On?
CureVac NV is listed and trades on the NASDAQ stock exchange.
Is CureVac NV a Good Stock to Buy?
Determining whether CureVac NV—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CVAC quote. (ISIN: NL0015436031)"
2.76
+0.04(+1.32%)
Delayed Data
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.74
2.80
52 wk Range
2.11
5.71
5CV Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.742.80
52 wk Range
2.115.71
Key Statistics
Edit
Fair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
Unlock5CV Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Price Target
6.89
Upside
+140.21%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- CureVac appoints new CFO to drive growth
- Investing.com
- CureVac N.V. Appoints Axel Sven Malkomes as CFO
- Investing.com
- CureVac appoints new CFO to drive growth
- Investing.com
CureVac NV Company Profile
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Compare 5CV to Peers and Sector
Metrics to compare | 5CV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship5CVPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.2x | −2.7x | −0.7x | |
PEG Ratio | −0.14 | −0.07 | 0.00 | |
Price/Book | 1.6x | 1.2x | 2.6x | |
Price / LTM Sales | 9.2x | 5.9x | 3.2x | |
Upside (Analyst Target) | - | 77.7% | 46.4% | |
Fair Value Upside | Unlock | 11.9% | 6.9% | Unlock |
FAQ
What Is the CureVac NV (5CV) Stock Price Today?
The CureVac NV stock price today is 2.76
What Stock Exchange Does CureVac NV Trade On?
CureVac NV is listed and trades on the Xetra stock exchange.
What Is the Stock Symbol for CureVac NV?
The stock symbol for CureVac NV is "5CV."
What Is the CureVac NV Market Cap?
As of today, CureVac NV market cap is 615.86M.
What is CureVac NV Earnings Per Share?
The CureVac NV EPS is -1.24.
What Is the Next CureVac NV Earnings Date?
CureVac NV will release its next earnings report on 22 Apr 2025.
From a Technical Analysis Perspective, Is 5CV a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.